HRTX HERON THERAPEUTICS, INC. /DE/ Insider Trading

Rubric Capital (10% owner) acquires 2.39M HRTX shares at $1.50; stock down 48.6% from 52-week high, now $1.31.

Rubric Capital Management LP, a substantial 10% shareholder, purchased 2,387,225 shares of Heron Therapeutics at $1.50 on 2025-08-08, increasing its stake by 8.9% to 29.10M shares. The transaction occurs as HRTX trades at $1.31, down 48.6% from its 52-week high of $2.55 and 39.9% over the past 30 days, signaling material near-term deterioration. The company remains unprofitable with a negative net income of $-2,381,000 in the latest quarter despite 13.6% annual revenue growth, suggesting operational headwinds despite topline expansion. The purchase represents a substantial $3.6M commitment by an insider with a cross-ticker track record averaging 1.8% positive returns on prior sells within 30 days—providing limited historical precedent for confidence in Rubric's tactical timing at this price level.

Director Morgan Adam bought 1.77M HRTX shares at $1.50 (Aug 2025), growing stake 25.3%; stock now -48.6% from 52-week high, unprofitable company.

Morgan Adam, a director of Heron Therapeutics, purchased 1,766,546 shares at $1.50 on 2025-08-08, increasing his holdings from 6.99M to 8.75M shares—a 25.3% increase in position size for $2.6M. The stock has declined significantly since the transaction, now trading at $1.31 (-48.6% from its 52-week high of $2.55) and down 39.9% over the prior 30 days, raising questions about execution timing. The company remains unprofitable with a net loss of $2.4M in the latest quarter despite positive annual revenue growth of 13.6%, and Adam's prior trade at this ticker (a July 2023 buy) produced a -53.5% return over 90 days—a poor outcome that provides limited precedent for timing success in HRTX. This purchase signals substantial capital commitment by a director to a distressed biotech position, yet the post-transaction price action and company's ongoing losses underscore material execution and fundamental risks investors should monitor closely.